# AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

> **NCT00396968** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** AMD3100
- **PROCEDURE:** Allogeneic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT00396968
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396968, "AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT00396968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*